Unity Biotechnology Inc - Company Profile
Powered by 
All the data and insights you need on Unity Biotechnology Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Unity Biotechnology Inc Strategy Report
- Understand Unity Biotechnology Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Unity Biotechnology Inc (Unity Biotechnology) develops and commercializes therapies for the treatment of age-related diseases. The company focuses on the development of senolytic medicines to eliminate senescent cells. Unity Biotechnology’s product portfolio includes UBX0101, intended for musculoskeletal diseases; and UBX1325, for age-related diseases, including diabetic retinopathy and diabetic macular edema, glaucoma and age-related macular degeneration. It involves in developing products for idiopathic pulmonary fibrosis, systemic sclerosis, chronic obstructive pulmonary disease, cognition and kidney disease. The company works in collaboration with research institutions, academic, contract research organizations to develop its product portfolio. Unity Biotechnology is headquartered in south San Francisco, California, the US.
Headquarters
United States of America
Address
285 East Grand Avenue, South San Francisco, California, 94080
Website
unitybiotechnology.com
Telephone
1 650 4161192
No of Employees
32
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
UBX (NASD)
Revenue (2021)
$236,000
-100%
(2021 vs 2020)
EPS
XYZ
Net Income (2022)
XYZ
10.4%
(2022 vs 2021)
Market Cap*
$25.2M
Net Profit Margin (2021)
XYZ
-1,384.5%
(2022 vs 2021)
* As of and is in US$
Unity Biotechnology Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| UBX1325: |
| Diabetic Macular Edema, Age-Related Macular Degeneration |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Unity Biotechnology Inc | RCM Technologies Inc | Pharma-Bio Serv Inc | AgeX Therapeutics Inc | Alaunos Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | South San Francisco | Pennsauken | Dorado | Alameda | Houston |
| State/Province | California | New Jersey | - | California | Texas |
| No. of Employees | 32 | 3,490 | 100 | 4 | 1 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Keith R. Leonard Jr. | Chairman | Executive Board | 2016 | 61 |
| Anirvan Ghosh, Ph.D | Chief Executive Officer; Director | Executive Board | 2020 | 59 |
| Nathaniel E. David | Co - Founder; President; Director | Executive Board | 2011 | 55 |
| Lynne Sullivan | Chief Financial Officer; Head - Corporate Development | Senior Management | 2020 | 57 |
| Jamie Dananberg | Chief Medical Officer | Senior Management | 2016 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer